Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
P/B ratio for Inspire Medical Systems, Inc. (INSP)
P/B ratio as of 2023: 10.41
According to Inspire Medical Systems, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 10.41. At the end of 2022 the company had a P/B ratio of 14.26.
P/B ratio history for Inspire Medical Systems, Inc. from 2015 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 10.41 |
| 2022 | 14.26 |
| 2021 | 27.38 |
| 2020 | 21.35 |
| 2019 | 12.63 |
| 2018 | 3.76 |
| 2017 | 227.09 |
| 2016 | -47.11 |
| 2015 | 0.00 |